Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors.

J Clin Med · 2020 · PMC7408792 · PMID 32679880

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Preliminary results from the OPTIC trial showed a trend toward dose-dependent efficacy and safety that may provide a better understanding of the ponatinib risk/benefit profile.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.